NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Status:
Recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
Cognitive impairment, the core psychopathology of schizophrenia, usually persists in
schizophrenia patients even during symptomatic remission. While cognitive impairment
associated with schizophrenia (CIAS) is an important therapeutic target, hypofunction of
N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. This study aims to examine the
efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia
patients during symptomatic remission.